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Abstract
Background: Human Immunodeficiency Virus (HIV) pandemic has exacerbated tuberculosis disease especially in
Sub-Saharan African countries. The World Health Organization (WHO) and Joint United Nations Program on HIV/
AIDS (UNAIDS) have recommended Isoniazid Preventive Therapy (IPT) for HIV infected patients to reduce the
burden of tuberculosis (TB). Ethiopia has been implementing IPT since 2007. However, effectiveness of IPT in
averting occurrence of active tuberculosis among HIV infected patients has not been assessed.
Methods: Retrospective cohort study was employed using secondary data from public health institutions of Addis
Ababa. Descriptive statistics and Generalized Linear Model based on Poisson regression was used for data analysis.
Results: From 2524 HIV infected patients who were followed for 4106 Person-Years, a total of 277 incident
Tuberculosis (TB) cases occurred. TB Incidence Rate was 0.21/100 Person-Year, 0.86/100 Person-Year & 7.18/100
Person-Year among IPT completed, in-completed and non-exposed patients, respectively. The adjusted Incidence
Rate Ratio (aIRR) among IPT completed vs. non-exposed patients was 0.037 (95% CI, 0.016-0.072). Gender, residence
area, employment status, baseline WHO stage of the disease (AIDS) and level of CD4 counts were identified as risk
factors for TB incidence. The aIRR among patients who took Highly Active Anti- Retroviral Therapy (HAART) with IPT
compared to those who took HAART alone was 0.063 (95% CI 0.035-0.104). IPT significantly reduced occurrence of
active TB for 3 years.
Conclusions: IPT significantly reduced tuberculosis incidence by 96.3% compared to IPT non-exposed patients.
Moreover concomitant use of HAART with IPT has shown a significant reduction in tuberculosis incidence by 93.7%
than the use of HAART alone. Since IPT significantly protected occurrence of active TB for 3 years, its
implementation should be further strengthened in the country.
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Background
Tuberculosis (TB) and Human Immunodeficiency virus/
Acquired Immunodeficiency Syndrome (HIV/AIDS) are
major public health threat [1–3]. Among HIV infected
patients, TB is the most frequent life threatening
opportunistic disease, even in those receiving Highly Ac-
tive Antiretroviral Therapy (HAART) and it has been
shown to be a leading cause of death [2, 4, 5]. HIV infec-
tion is also the strongest risk factor for TB disease [3].
In 2011, globally there were 34 million HIV infected
patients and at least one-third of these had latent TB &
1.1 million of them developed new TB infection, of these
around 79% of patients were from Sub-Saharan African
countries, indicating that HIV is fueling the TB epi-
demics in the region [5]. In Ethiopia like many of the
developing countries, TB has created major burden to
the health care system due to its linkage with HIV/AIDS
Table 1 Socio-demographic characteristics of patients at
enrollment for chronic HIV care in public health facilities of
Addis Ababa, during 2007-June 2012
Socio-demographic
profile at enrollment for











Male 473(37.4) 469(37.2) 942(37.3) 0.918
Female 791(62.6) 791(62.8) 1582(62.7)
Age in years (mean = 34.9, SD = 9.1)
<30 421(33.3) 557(44.2) 978(38.7) 0.150
30–39 408(32.3) 412(32.7) 820(32.5)
40–49 283(22.4) 247(19.6) 530(21)
>50 152(12) 44(3.5) 196(7.8)
Marital status
Single 318(25.2) 288(22.9) 606(24) 0.000
Married 584(46.2) 551(43.7) 1135(45)
Widowed 189(15) 195(15.5) 384(15.2)
Separated 157(12.4) 165(13.1) 322(12.8)
Divorced 16(1.3) 61(4.8) 77(3.1)
Level of Education
No formal education 248(19.6) 276(21.9) 524(20.8) 0.004
Primary completed 507(40.1) 447(35.5) 954(37.8)
Secondary completed 473(37.4) 473(37.5) 946(37.5)
Tertiary completed 36(2.8) 64(5.1) 100(4)
Religion
Orthodox 979(77.5) 1023(81.2) 2002(79.3) 0.197
Muslim 98(7.8) 177(14) 275(10.9)
Protestant 132(10.4) 54(4.3) 236(9.4)
Othersa 5(0.4) 6(0.5) 11(0.4)
Employment status
Non-employed 650(51.4) 483(38.3) 1133(44.9) 0.000




Private 183(14.5) 270(21.4) 453(17.95)
Student 8(0.63) 12(0.95) 20(0.8)
Residence place
Addis Ababa 1230(97.3) 1252(99.4) 2482(98.3) 0.322
Out of Addis Ababa 34(2.7) 8(0.6) 42(1.7)
Average no. of personnel
per family
3.15 3.45 3.3 0.092
Average no. of rooms
per family
1.35 1.65 1.5 0.593
aCatholic and Joba
Table 2 Baseline clinical information of HIV positive patients in
public health facilities of Addis Ababa, during 2007-June 2012
Baseline Clinical










Initial WHO stage of HIV/AIDS
Stage 1 357(28.2) 215(17.1) 572(22.7) 0.000
Stage 2 487(38.5) 346(27.5) 833(33)
Stage 3 392(31) 580(46) 972(38.5)
Stage 4 28(2.3) 119(9.4) 147(5.8)
Baseline CD4cells count/μl(mean = 230, SD = 176.9)
≤200 570(45.1) 807(64) 1377(54.6) 0.000
>200 694(54.9) 453(36) 1147(45.4)
Initial body weight in Kg (mean = 53.8, SD = 9.7)
<50 304(24.1) 554(43.8) 858(34) 0.009
50–59 628(49.7) 418(33.1) 1046(41.4)
60–69 208(16.5) 214(17) 422(16.7)
>69 124(9.8) 74(5.9) 198(7.8)
TB screeneda
Positive 0 40(3.2) 40(1.6)
Negative 1264(100) 1220(96.8) 2484(98.4)
On CPT
Yes 1259(99.6) 1205(95.6) 2464(97.6) 0.000
No 5(0.4) 55(4.4) 60(2.4)
OIs diagnosed
None 1082(85.6) 907(71.9) 1989(78.8) 0.000
Bacterial infections 11(0.87) 164(13) 175(6.9)
Viral infections 25(0.08) 88(6.9) 113(4.5)










aA patient is TB positive, if he/she has at least two of these signs/symptoms:
Weight loss greater than or equal to 5% of the initial weight, coughing for
2 weeks, night sweat, night-mar, Loss of appetite
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epidemics [6]. In 2010, TB incidence in HIV-positive pa-
tients was 48 (27–76) per 100,000 population and the
prevalence of TB including among HIV positives was
572(265–947) per 100,000 population [7].
Since 1998, WHO and the Joint United Nations Program
on HIV/AIDS (UNAIDS) have recommended Isoniazid
Preventive Therapy (IPT) as one of the key interventions
in the comprehensive HIV/AIDS care strategy to reduce
the burden of TB among HIV infected patients [8].
According to WHO [2], IPT given to HIV infected patients
without TB disease reduces the risk of developing TB by
33–67% for up to 48 months. Regarding the concomitant
use of HAART with IPT, a meta-analysis led by WHO
found out that HAART reduces the individual risk of TB
disease by 65%, irrespective of the CD4 cell count but
recent evidence has shown that the combined use of IPT
and HAART among HIV infected patients significantly
reduces the incidence of TB by up to 97% [9].
In Ethiopia, IPT provision for HIV infected patients is
recommended by the national TB/HIV Collaborative
Activities guideline and its implementation has been
started since 2007[10]. However, the effectiveness of IPT
in reducing the burden of active TB among HIV infected
patients relative to those who did not take or discontin-
ued has not been assessed yet. Moreover the clinical and
programmatic factors affecting the treatment outcome
among those who took have not been clearly identified.
Therefore, this study assessed the effectiveness of the
provision of IPT for HIV infected patients in averting
occurrence of TB in the Ethiopian context.
Methods
A multi-centered retrospective cohort study design was
employed using secondary data from 14 public health
facilities giving ART service in Addis Ababa. From seven
facilities which were giving IPT service between 2007
and January 2010, all adult HIV positive patients (1264)
who were either on HAART or Pre-ART and exposed to
IPT in the study period and who were followed for at
Table 3 Clinical information of patients who were unheard












WHO stage of HIV/AIDS
Stage 1 151(16.02) 138(12.5) 289(14.1) 0.000
Stage 2 367(39) 294(26.6) 661(32.3)
Stage 3 394 (41.8) 551(49.9) 945(46.2)
Stage 4 30 (3.18) 121(11.0) 151(7.4)
CD4cells count/μl(mean = 151.2, SD = 84.9)
≤200 537 (37.9) 1020(92.4) 1557(76.1) 0.000
>200 263 (27.9) 226(20.5) 489(23.9)
Weight in Kg (mean = 53.2, SD = 9.5)
<50 241(25.6) 506(45.8) 747(36.5) 0.011
50–59 479(44.2) 366(33.1) 845(41.3)
60–69 164 (17.4) 164(14.9) 328(16.0)
>69 58 (6.2) 68(6.2) 126(6.2)
TB screened
Yes 942(100) 1100(99.6) 2042(99.8) 0.64
No 0 4(0.4) 4(0.2)
CPT adherence
Good 791(84) 1096(99.3) 2032(99.6) 0.046
Fair 3(.32) 6(0.5) 9(0.3)
Poor 3(.32) 2(0.2) 5(0.2)
ART adherence
Good 937(99.5) 1100(99.6) 2037(99.6) 0.124
Fair 5(0.53) 2(0.2) 7(0.3)
Poor 0 2(0.2) 2(0.1)
OIs after ART initiated
None 937(99.5) 1052(95.3) 1989(97.21) 0.000
Fungal 3(.32) 20(1.8) 23(1.12)
Viral 0 12(1.0) 12(0.5)
Bacterial 0 12(1.0) 14(0.7)
Bacterial & fungal 0 4(0.4) 4(0.2)
Othersa 0 4(0.4) 4(0.2)
aProtozoal, viral & bacterial & fungal & viral infections
Table 4 Profile of IPT exposed patients inpublic health facilities
of Addis Ababa, during 2007-June 2012




TB screened & tested negative 1264(100%)
Currently on HAART 942(74.5%)
Pre-ART 322(25.5%)
HAART initiated before IPT 578(61.3%)
HAART initiated after IPT 364(38.7%)
IPT completed 975(77.1%)
IPT discontinued 289(22.9%)
On HAART + IPT completed 738(78.3%) 0.094
Pre-ART + IPT completed 237(73.6%)
On HAART + IPT in-completed 204(21.7%) 0.08
Pre-ART + IPT in-completed 85(26.4%)
Male IPT completed 359(75.9%) 0.459
Female IPT completed 616(77.8%)
Took B6 together with INH 581(46%)
No IPT side effects 1254(99.2%)
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least a year were included as IPT exposed patients. All
IPT discontinued patients regardless of their follow up
time were also included. For comparison, equivalent
number of non- IPT exposed patients who were on HIV
care management for 1 or more years were sampled
from randomly selected facilities which were not provid-
ing IPT till January 2010. All pediatric HIV positive
patients regardless of whether they took/did not take
IPT in the study period set, and all transferred in pa-
tients were excluded from this study. The patient charts
from each facility were selected by random sampling
method. A structured data abstraction format was used
to collect information from medical records/chart of
patients and the data was collected from July 1 to
August 31, 2012. The data was entered and processed
using SPSS version 16 statistical software. Descriptive
statistics for patient characterization, Generalized Linear
Model based on Poisson distribution to get incidence
rate and incidence rate ratio, nonparametric test and Chi
Square test were used for statistical analysis.
Results
A total of 2528 patients’ charts were reviewed and four
charts were with incomplete information and hence
only 2524 charts were included in analysis. Of these,
1582(62.7%) were female and their mean age was
Table 5 Incidence rate, univariate and multivariate analysis
among IPT completed, in-completed and non- exposed patients
in public health facilities of Addis Ababa, during 2007-June 2012




Over all 277/4106 6.7
IPT completed 7/33.3 0.21 0.03(0.01–0.06) 0.04(0.05–0.07)
IPT in-
completed
8/7.8 0.86 0.84(0.36–1.33) 0.89(0.49–1.76)
IPT non-exposed 262/36.49 7.18 1 1
Sex
Male 138/2822.1 4.89 1.80(1.42–2.28) 1.59(1.20–2.12)
Female 139/5129.2 2.71 1 1
Age group in year
<30 103/3038.3 3.39 1 1
30–39 87/2628.4 3.31 0.98(0.73–1.29) 0.82(0.61–1.11)
40–49 61/1644.2 3.71 1.09(0.79–1.49) 1.04(0.74–1.47)




4/135.1 2.96 0.85(0.26–1.99) 0.29(0.09–0.73)
Living in
Addis Ababa
273/7800 3.50 1 1
Religion
Orthodox 231/6243.2 3.70 0.63(0.20–3.82) 0.29(0.08–1.86)
Muslim 19/892 2.13 0.36(0.11–2.28) 0.17(0.04–1.13)
Protestant 25/778.8 3.21 0.55(0.16–3.40) 0.32(0.09–2.12)
Others* 11/187.7 5.86 1 1
Marital status
Married 127/3547.5 3.58 0.82(0.46–1.68) 1.22(0.66–2.51)
Single 72/1889.8 3.81 0.88(0.48–1.81) 1.18(0.63–2.48)
Widowed 33/1284 2.57 0.59(0.30–1.27) 0.81(0.40–1.76)
Divorced 35/997.2 3.51 0.81(0.45–1.72) 1.05(0.53–2.27)
Separated 10/229.9 4.35 1 1
Employment
Self employed 87/3782.6 2.30 0.03(0.01–0.19) 0.02(0.01–0.12)
Private
Employed
58/1418.1 4.09 0.06(0.02–0.35) 0.03(0.01–0.16)
Government
employed
62/1324.8 4.68 0.07(0.02–0.40) 0.03(0.01–0.19)
Student 3/66.5 4.51 0.06(0.01–0.48) 0.01(0.002–0.101)
Non- employed




42/1707.3 2.46 0.65(0.35–1.33) 1.25(0.62–2.70)
Primary
Completed
106/3028.6 3.50 0.93(0.52–1.83) 1.69(0.89–3.49)
Secondary
Completed
118/2920.8 4.04 1.07(0.60–2.10) 1.76(0.97–3.55)
Tertiary
completed
11/291 3.78 1 1
Table 5 Incidence rate, univariate and multivariate analysis
among IPT completed, in-completed and non- exposed patients





Baseline WHO stage of HIV/AIDS
Stage 1 & 2 45/4545.5 0.99 0.14(0.10–0.19) 0.23(0.16–0.31)
Stage 3 & 4 232/3381.9 6.86 1
Baseline CD4
cells/μl
≤200 211/4169.9 5.06 2.89(2.21–3.85) 1.36(1.02–1.84)
>200 66/3771.4 1.75
Baseline weight in Kg
≤49 113/2646.4 4.27 1.88(1.12–3.43) 1.63(0.93–3.05)
50–59 108/3343.7 3.23 1.42(0.85–2.59) 1.19(0.69–2.22)
60–69 42/1333.3 3.15 1.39(0.78–2.64) 1.06(0.59–2.03)
>69 14/616.7 2.27 1 1
Baseline OIs
Yes 194/6278.3 3.09 0.62(0.48–0.80) 1.24(0.95–1.63)
No 83/1660 5.00 1 1
CPT adherence
Good 271/7765 3.49 0.99(0.48–2.51) 0.92(0.44–2.37)
Fair, Poor &
no CPT
2/56.8 3.52 1 1
*others include: catholic, johoba and non belivers
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34.9 years. Majority were married and from Orthodox
family. A significant proportion (44.9%) was un-employed.
There is significant difference in level of education, marital
status and employment status (Table 1).
All of the patients were Pre-ART at the time of enroll-
ment for chronic HIV care and the baseline clinical in-
formation of the patients is shown in Table 2. Majority
of the patients were in stage 3 followed by stage 2, 972
(38.5%) and 833 (33%), respectively. There was signifi-
cant clinical difference between the two groups.
As shown in Table 3, from all patients for whom their
charts were reviewed, 2046 (81.1%) had initiated HAART
during their follow up; of whom 945 (46.2%) of them were
WHO stage 3.
Out of 1264 patients who were given IPT, completion
rate was 975(77.1%). Among IPT exposed patients;
942(74.5%) were on HAART and of these 738(78.3%)
completed IPT (Table 4).
Among 2524 HIV-infected patients who were followed
for 4106 P-Y, 277 incident TB cases occurred, making the
overall incidence of 6.7/100P-Y. Among IPT completed
group, incidence rate was 0.21/100PY, while in IPT non-
exposed patients; it was 7.18/100P-Y. Incidence of TB was
found to be associated with sex, employment status,
baseline WHO stage of HIV/AIDS and CD4 count.
Completion of IPT showed significant protective effect
against occurrence of active TB when compared to IPT
non-exposed patients aIRR = 0.037 (CI 95% 0.016-0.072)}
(Table 5, Fig. 1).
Similarly, as shown in Table 6 and Fig. 2, those pa-
tients who took IPT with HAART had TB incidence rate
of 0.42/100P-Y and among patients who took HAART
alone, the incidence was 7.83/100P-Y. The concomitant
use of IPT with HAART revealed significant protective
effect on occurrence of active TB compared to HAART
alone {aIRR =0.063(95% CI 0.035-0.104). Among IPT
exposed patients, those who took IPT with HAART had
lesser incidence than those who took IPT before initiat-
ing HAART {aIRR = 0.158(95% CI 0.039- 0.555)}.
As shown in Table 7, there was significant CD4 and
weight changes among IPT-HAART treated patients.
The median duration of follow- up was 40 months
(inter-quartile range, 28–52 months). From those who
completed IPT, active TB has occurred between 6 and
28 months duration. Almost 50% of patients who com-
pleted IPT developed active TB at 19thmonth; while in
non-exposed patients TB occurred within a month time of
enrollment (Table 8).
As shown in Table 9, IPT completers were signifi-
cantly protected for 3 years {aIRR = 0.04 (95% CI
(0.02-1.74)} compared to IPT in-completed and non-
exposed patients.
Fig. 1 Incidence rate among IPT completed, in-completed and non- exposed patientsin public health facilities of Addis Ababa, during
2007-June 2012
Table 6 IR & IRR among patients who took HAART with or
without IPT in public health facilities of Addis Ababa, during
2007-June 2012
Therapy (N = 1842) IR/100P-Y aIRR(95% CI)
IPT with HAART 0.42 0.063(0.035–0.104)
HAART only 7.83 1
IPT initiation time with HAART
Took IPT with HAART 0.2 0.158(0.039–0.555)
Took IPT before initiating HAART 0.75 1
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Discussion
This retrospective cohort study covering the time from
2007 to June 2012 attempted to assess effectiveness of
IPT against active TB in HIV positive adults who were on
HIV care in government health facilities of Addis Ababa.
Accordingly, the IRs were 0.21/100P-Y, 0.86/100P-Y &
7.18/100P-Y among IPT completed, in-completed & non-
exposed patients, respectively. The IR among IPT com-
pleted patients was lower when compared with the find-
ings of studies done in different countries [11–13].
Moreover, completion of IPT in HIV infected adults
significantly reduced TB incidence by 96.3% when com-
pared to non-exposed patients (aIRR = 0.037, 95% CI
0.016-0.072). The present study revealed abetter reduction
in TB incidence after IPT in comparison with the results
of earlier studies [7, 14–16]. Better patient adherence rate,
difference in TB burden among the countries or better
socioeconomic and clinical status of patients might have
contributed to such differences among studies conducted
in different countries. Despite the fact that Ethiopia is
among high TB burden country, IR among IPT completed
patients was comparably lower than studies indicating
further the effectiveness of IPT for HIV infected patients.
Hence more widespread provision of IPT has the potential
to further reduce TB incidence and hence improve quality
of life among HIV infected adults in the country.
Among patients who completed IPT, though TB had
occurred after 6 months, almost 50% of them developed
TB at 19thmonth; while in IPT non-exposed patients,
half of patients developed active TB within a month
time. The study proved that IPT has been significantly
protecting early occurrence of TB during the first
6 months. This finding was comparable to the study
done in Thailand where IR among IPT completers was
0 and among non-exposed patients 8.60/100 P-Y [17].
Moreover, the present study indicated that IPT had of-
fered a significant protective effect until 3 years. The
durability of protective effect of IPT documented in the
present study concurs with the expected level indicated
in Ethiopian guideline [10]. It is, however, better than
reports from South East Asian and other Sub-Saharan
African countries [13, 17, 18].
With regard to risk factors associated with TB occur-
rence, even though there is significant difference among
the two groups in socio-demographic and baseline clin-
ical characteristics, the multivariable analysis revealed
significant influence of IPT completion, male sex, em-
ployment status, baseline WHO stage of HIV/AIDS
(stage 3 & 4) & CD4 cell count (less than 200cells/μl).
Similarly, South African and Namibian studies indi-
cated the influence of clinical factors on the incidence of
Tb among HIV patients [13, 16].
Getahun et al. [19] reported that in countries with a
high prevalence of HIV, more women than men are
Fig. 2 IR among patients who took HAART with IPT in public health facilities of Addis Ababa, during 2007-June 2012
Table 7 Statistical analysis of clinical data among patients who






IPT – weight at enrollment
Negative Ranks 160a 410.64




IPT - CD4 at enrollment
Negative Ranks 253d 546.73
Positive Ranks 702e 453.23 0.000
Ties 21f
Total 976
aWeight when completing IPT < weight when starting IPT
bWeight when completing IPT > weight when starting IPT
cWeight when completing IPT = weight when starting IPT
dCD4 when completing IPT < CD4 when starting IPT
eCD4 when completing IPT > CD4 when starting IPT
fCD4 when completing IPT = CD4 when starting IPT
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diagnosed with TB. But the current study revealed that
more males who took IPT were at risk of developing
active TB than females (aIRR = 1.596(95% CI = 1.203-
2.117). This was in agreement with the report made by
Golub et al. [20].
Concerning IPT initiation time with HAART, among
IPT exposed patients; those patients who took IPT with
HAART had 84.2% incidence reduction than those who
took IPT prior to initiating HAART. This study also
noted that there was significant CD4cell count and
weight changes after taking IPT-HAART combination
therapy compared to cell count at enrollment, which
might have contributed for preventing TB recurrence.
This finding could serve as a base for further studies to
reach an understanding on whether concomitant initi-
ation of IPT with HAART or delayed initiation of IPT is
better in terms of efficacy, toxicity or the development
of immune reconstitution. In general the current finding
encourages further implementation of the therapy in the
country so as to decrease the burden of TB among HIV
infected patients.
Conclusions
Completion of IPT significantly reduced TB incidence by
96.3% and IPT had significantly protected occurrence of
active TB for three years among HIV infected patients.
Male sex, CD4 cell count less than 200cells/μl, WHO
stage of HIV/AIDS 3 & 4 and being non-employed were
risk factors for TB incidence. Concomitant use of
HAART with IPT significantly decreased TB incidence
by 93.7% more than HAART alone. This result evi-
denced and supported the WHO recommendations that
IPT protected the occurrence of active TB and proved
the effectiveness of IPT in reducing TB incidence among
Table 8 Month of occurrence of active TB among IPT completed, in-completed & non-exposed patients in public health facilities of
Addis Ababa, during 2007-June 2012











Month TB occurred among IPT
completed patients
7 6 28 16.7 8.4 19
Month TB occurred among patients
who discontinued IPT
8 0 35 9.6 14.8 0
Month TB occurred among IPT
non-exposed
262 0 65 8.1 13.3 1
Table 9 TB incidence in month interval among IPT completed, in-completed & non-exposed patients in public health facilities of











<6 Completed 0 0 0
In-complete 142.8(17.64–268.07) 1.82(0.65–3.97) 2.125(0.712–5.103)
Non-exposed 78.59(66.9–90.3) 1 1
6–12 Completed 12(1.58–25.58) 0.30(0.06–0.79) 0.03(0.013–1.95)
In-completed 38.71(7.74–69.68) 0.98(0.39–2.02) 1.05(0.32–2.89)
Non-exposed 39.43(34.05–44.82) 1 1
12–24 Completed 6.74(1.35–12.14) 0.29(0.11–0.59) 0.03(0.01–0.74)
In-completed 38.71(7.74–69.68) 1.65(0.65–3.38) 1.61(0.51–4.29)
Non-exposed 23.51(20.48–26.55) 1 1
24–36 Completed 5.98(1.55–10.42) 0.34(0.14–0.66) 0.04(0.02–1.74)
In-completed 9.94(3.05–16.82) 0.56(0.25–1.05) 1.09(0.49–2.54)
Non-exposed 17.87(15.63–20.11) 1 1
37–48 Completed 5.98(1.55–10.42) 0.44(0.186–0.854) 0.74(0.301–1.56)
In-completed 9.94(3.05–16.82) 0.73(0.33–1.37) 0.72(0.314–1.44)
Non-exposed 13.72(12.04–19.56 1 1
>48 Completed 5.98(1.55–10.42) 0.50(0.22–0.99) 0.88(0.36–1.84)
In-completed 9.94(3.05–16.82) 0.84(0.38–1.58) 0.89(0.39–1.76)
Non-exposed 11.88(10.44–13.32) 1 1
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HIV infected patients in Ethiopia. Therefore, it should
be implemented widely for HIV-infected patients in all
parts of the country so as to improve their quality of life
by reducing the TB burden and prevent further trans-
mission of TB in the community.
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